Q-omics provides the consensus-scored RPL36P16 profile across patient tissues and cancer cell-line models. RPL36P16 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in ACC. Among the 18 cancer types available for tumor–normal comparison, RPL36P16 is differentially expressed in 7, with the highest sampling consensus in COAD. Additionally, RPL36P16 RNA expression shows 8,485 significant gene co-expression associations, with the highest sampling consensus in ESCA. Together, these results highlight ACC, COAD, and ESCA as cancer lineages where RPL36P16 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for RPL36P16 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes RPL36P16 survival associations across molecular data types. RPL36P16 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible RPL36P16 RNA expression–survival associations across cancer types. High RPL36P16 expression shows unfavorable associations in ACC, BRCA and KIRC, but favorable associations in ESCA, MESO and PAAD. The ACC Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify ACC as the clearest survival context for RPL36P16 RNA expression.
This table summarizes RPL36P16 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 7. The strongest signals are observed in COAD for RNA.
This table ranks reproducible tumor–normal expression differences for RPL36P16. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. RPL36P16 shows higher tumor expression in COAD, KIRC, STAD, BRCA, READ and KIRP. The COAD box plot shows higher RPL36P16 RNA expression in tumor versus normal tissue (log2 FC = +1.047, t-test p < 0.001).
This table shows molecular features associated with RPL36P16 in patient tissues and cancer cell lines. In patient samples, RPL36P16 shows the broadest associations at the RNA and protein expression levels, with ESCA recurring as the lineage with the largest associated feature set.
